Advertisement

Current Heart Failure Reports

, Volume 15, Issue 3, pp 161–170 | Cite as

Contraceptive Strategies in Women With Heart Failure or With Cardiac Transplantation

  • Anjli Maroo
  • Johnny Chahine
Pharmacologic Therapy (W.H.W. Tang, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Pharmacologic Therapy

Abstract

Purpose of Review

We describe contraception for two groups of women: (1) women with heart failure and (2) women with cardiac transplantation.

Recent Findings

Medical Eligibility Criteria for contraceptive agents address women with peripartum cardiomyopathy and women with valvular heart disease (Curtis et al. MMWR Recomm Rep 65:1–103, 2016). Recommendations for women with other forms of heart failure are extrapolated from these populations. Recommendations for women with cardiac transplantation have shifted since the 1980s: use of long-acting reversible contraception has increased, and there is a better understanding of the interactions between contraceptive and immunosuppressive regimens.

Summary

Women with heart failure may utilize long-acting reversible contraception and permanent sterilization. Modifications should be made according to the specific etiology of the heart failure. In women with cardiac transplantation, pregnancy is high risk and should be avoided altogether for 1–2 years after transplantation. In uncomplicated transplantation, almost all forms of contraception are allowable. In complicated transplantation, combined hormonal contraceptives are contraindicated, and de novo IUD insertion is not recommended.

Keywords

Contraception Cardiac transplantation Heart failure Cardiomyopathy Estrogen and progesterone Intrauterine device 

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Estensen M, Gude E, Ekmehag B, Lommi J, Bjortuft O, Mortensen S, et al. Pregnancy in heart- and heart/lung recipients can be problematic. Scand Cardiovasc J. 2011;45:349–53.CrossRefPubMedGoogle Scholar
  2. 2.
    Grewal J, Silversides CK, Colman JM. Pregnancy in women with heart disease: risk assessment and management of heart failure. Heart Fail Clin. 2014;10:117–29.CrossRefPubMedGoogle Scholar
  3. 3.
    Abdalla M, Mancini DM. Management of pregnancy in the post-cardiac transplant patient. Semin Perinatol. 2014;38:318–25.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Roos-Hesselink JW, Duvekot JJ, Thorne SA. Pregnancy in high risk cardiac conditions. Heart. 2009;95:680–6.CrossRefPubMedGoogle Scholar
  5. 5.
    •• Curtis KM, Tepper NK, Jatlaoui TC, Berry-Bibee E, Horton LG, Zapata LB, et al. U.S. medical eligibility criteria for contraceptive use, 2016. MMWR Recomm Rep. 2016;65:1–103. The Centers for Disease Control and Prevention Medical Eligibility Criteria (CDC-MEC) document provides guidelines for use of contraceptive agents in multiple different populations, including patients with cardiac risk factors, heart failure, and solid organ transplantation. Google Scholar
  6. 6.
    • World Health Organization Medical Eligibility Criteria for Contraceptive Use, Fifth Edition. Geneva. 2015. WHO reference number: WHO/RHR/15.07. The World Health Organization Medical Eligibility Criteria document also provides guidelines for mutiple different populations. Google Scholar
  7. 7.
    • World Health Organization Medical Eligibility Criteria for Contraceptive Use, Fourth Edition. Geneva. 2010. The World Health Organization Medical Eligibility Criteria document also provides guidelines for mutiple different populations. Google Scholar
  8. 8.
    • Coscia LA, Constantinescu S, Moritz MJ, Frank AM, Ramirez CB, Maley WR, Doria C, McGrory CH, Armenti VT. Report from the national transplantation pregnancy registry (ntpr): outcomes of pregnancy after transplantation. Clin Transpl. 2010;7:65–85. The NTPR collects outcome data on patients with solid organ transplant, including cardiac transplant, who undergo pregnancy. Google Scholar
  9. 9.
    Thorne S, MacGregor A, Nelson-Piercy C. Risks of contraception and pregnancy in heart disease. Heart. 2006;92:1520–5.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Tran DD, Kobashigawa J. A review of the management of pregnancy after cardiac transplantation. Clin Transpl. 2015;31:151–61.PubMedGoogle Scholar
  11. 11.
    Milsom I, Korver T. Ovulation incidence with oral contraceptives: a literature review. J Fam Plann Reprod Health Care. 2008;34:237–46.CrossRefPubMedGoogle Scholar
  12. 12.
    Grandi G, Cagnacci A, Volpe A. Pharmacokinetic evaluation of desogestrel as a female contraceptive. Expert Opin Drug Metab Toxicol. 2014;10:1–10.CrossRefPubMedGoogle Scholar
  13. 13.
    Lawrie TA, Helmerhorst FM, Maitra NK, Kulier R, Bloemenkamp K, Gulmezoglu AM. Types of progestogens in combined oral contraception: effectiveness and side-effects. Cochrane Database Syst Rev. 2011;11(5):CD004861.  https://doi.org/10.1002/14651858.CD004861.pub2.
  14. 14.
    Erkkola R, Landgren BM. Role of progestins in contraception. Acta Obstet Gynecol Scand. 2005;84:207–16.CrossRefPubMedGoogle Scholar
  15. 15.
    Giribela CR, Consolim-Colombo FM, Nisenbaum MG, Moraes TL, Giribela AH, Baracat EC, et al. Effects of a combined oral contraceptive containing 20 mcg of ethinylestradiol and 3 mg of drospirenone on the blood pressure, renin-angiotensin-aldosterone system, insulin resistance, and androgenic profile of healthy young women. Gynecol Endocrinol. 2015;31:912–5.CrossRefPubMedGoogle Scholar
  16. 16.
    Nisenbaum MG, de Melo NR, Giribela CR, de Morais TL, Guerra GM, de Angelis K, et al. Effects of a contraceptive containing drospirenone and ethinyl estradiol on blood pressure and autonomic tone: a prospective controlled clinical trial. Eur J Obstet Gynecol Reprod Biol. 2014;175:62–6.CrossRefPubMedGoogle Scholar
  17. 17.
    Cardoso F, Polonia J, Santos A, Silva-Carvalho J, Ferreira-de-Almeida J. Low-dose oral contraceptives and 24-hour ambulatory blood pressure. Int J Gynaecol Obstet. 1997;59:237–43.CrossRefPubMedGoogle Scholar
  18. 18.
    Boldo A, White WB. Blood pressure effects of the oral contraceptive and postmenopausal hormone therapies. Endocrinol Metab Clin N Am. 2011;40:419–32. ix CrossRefGoogle Scholar
  19. 19.
    Christy NP, Shaver JC. Estrogens and the kidney. Kidney Int. 1974;6:366–76.CrossRefPubMedGoogle Scholar
  20. 20.
    Khalil RA. Estrogen, vascular estrogen receptor and hormone therapy in postmenopausal vascular disease. Biochem Pharmacol. 2013;86:1627–42.CrossRefPubMedGoogle Scholar
  21. 21.
    Stachenfeld NS. Hormonal changes during menopause and the impact on fluid regulation. Reprod Sci. 2014;21:555–61.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Petitti DB, Sidney S, Bernstein A, Wolf S, Quesenberry C, Ziel HK. Stroke in users of low-dose oral contraceptives. N Engl J Med. 1996;335:8–15.CrossRefPubMedGoogle Scholar
  23. 23.
    Lidegaard O, Lokkegaard E, Jensen A, Skovlund CW, Keiding N. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med. 2012;366:2257–66.CrossRefPubMedGoogle Scholar
  24. 24.
    de Bastos M, Stegeman BH, Rosendaal FR, Van Hylckama Vlieg A, Helmerhorst FM, Stijnen T, Dekkers OM. Combined oral contraceptives: venous thrombosis. Cochrane Database Syst Rev. 2014;3(3):CD010813.  https://doi.org/10.1002/14651858.CD010813.pub2.
  25. 25.
    Lidegaard O, Lokkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ. 2009;339:b2890.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Kemmeren JM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ. 2001;323:131–4.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Gronich N, Lavi I, Rennert G. Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: a population-based cohort study. CMAJ. 2011;183:E1319–25.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Sedlak T, Shufelt C, Iribarren C, Lyon LL, Bairey Merz CN. Oral contraceptive use and the ecg: evidence of an adverse qt effect on corrected qt interval. Ann Noninvasive Electrocardiol. 2013;18:389–98.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Sedlak T, Shufelt C, Iribarren C, Merz CN. Sex hormones and the qt interval: a review. J Women's Health (Larchmt). 2012;21:933–41.CrossRefGoogle Scholar
  30. 30.
    Abu-Zeitone A, Peterson DR, Polonsky B, McNitt S, Moss AJ. Oral contraceptive use and the risk of cardiac events in patients with long qt syndrome. Heart Rhythm. 2014;11:1170–5.CrossRefPubMedGoogle Scholar
  31. 31.
    Tepper NK, Dragoman MV, Gaffield ME, Curtis KM. Nonoral combined hormonal contraceptives and thromboembolism: a systematic review. Contraception. 2017;95:130–9.CrossRefPubMedGoogle Scholar
  32. 32.
    Sidney S, Cheetham TC, Connell FA, Ouellet-Hellstrom R, Graham DJ, Davis D, et al. Recent combined hormonal contraceptives (chcs) and the risk of thromboembolism and other cardiovascular events in new users. Contraception. 2013;87:93–100.CrossRefPubMedGoogle Scholar
  33. 33.
    Hussain SF. Progestogen-only pills and high blood pressure: is there an association? A literature review. Contraception. 2004;69:89–97.CrossRefPubMedGoogle Scholar
  34. 34.
    Wang Q, Wurtz P, Auro K, Morin-Papunen L, Kangas AJ, Soininen P, et al. Effects of hormonal contraception on systemic metabolism: cross-sectional and longitudinal evidence. Int J Epidemiol. 2016;45:1445–57.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Grimes DA, Lopez LM, O'Brien PA, Raymond EG. Progestin-only pills for contraception. Cochrane Database Syst Rev. 2013;13(11):CD007541.  https://doi.org/10.1002/14651858.CD007541.pub3.
  36. 36.
    Dilshad H, Ismail R, Naveed S, Usmanghani K, Alam MT, Sarwar G. Effect of hormonal contraceptives on serum lipids: a prospective study. Pak J Pharm Sci. 2016;29:1379–82.PubMedGoogle Scholar
  37. 37.
    Kongsayreepong R, Chutivongse S, George P, Joyce S, McCone JM, Garza-Flores J, et al. A multicentre comparative study of serum lipids and apolipoproteins in long-term users of dmpa and a control group of iud users. World Health Organization. Task force on long-acting systemic agents for fertility regulation special programme of research, development and research training in human reproduction. Contraception. 1993;47:177–91.CrossRefPubMedGoogle Scholar
  38. 38.
    Berenson AB, Rahman M, Breitkopf CR, Bi LX. Effects of depot medroxyprogesterone acetate and 20-microgram oral contraceptives on bone mineral density. Obstet Gynecol. 2008;112:788–99.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Villas-Boas J, Vilodre LC, Malerba H, Pontremoli Salcedo M, Foresti Jimenez M, El Beitune P. Metabolic safety of the etonogestrel contraceptive implant in healthy women over a 3-year period. Eur J Obstet Gynecol Reprod Biol. 2016;202:51–4.CrossRefPubMedGoogle Scholar
  40. 40.
    Guazzelli CA, de Queiroz FT, Barbieri M, Torloni MR, de Araujo FF. Etonogestrel implant in adolescents: evaluation of clinical aspects. Contraception. 2011;83:336–9.CrossRefPubMedGoogle Scholar
  41. 41.
    Tisdale JE, Jaynes HA, Overholser BR, Sowinski KM, Flockhart DA, Kovacs RJ. Influence of oral progesterone administration on drug-induced qt interval lengthening: a randomized, double-blind, placebo-controlled crossover study. JACC Clin Electrophysiol. 2016;2:765–74.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Zigler RE, McNicholas C. Unscheduled vaginal bleeding with progestin-only contraceptive use. Am J Obstet Gynecol. 2017;216:443–50.CrossRefPubMedGoogle Scholar
  43. 43.
    Diedrich JT, Desai S, Zhao Q, Secura G, Madden T, Peipert JF. Association of short-term bleeding and cramping patterns with long-acting reversible contraceptive method satisfaction. Am J Obstet Gynecol. 2015;212:50 e51–8.CrossRefGoogle Scholar
  44. 44.
    Moss C, Isley MM. Sterilization: a review and update. Obstet Gynecol Clin N Am. 2015;42:713–24.CrossRefGoogle Scholar
  45. 45.
    Glasier AF, Cameron ST, Fine PM, Logan SJ, Casale W, Van Horn J, et al. Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis. Lancet. 2010;375:555–62.CrossRefPubMedGoogle Scholar
  46. 46.
    Shen J, Che Y, Showell E, Chen K, Cheng L. Interventions for emergency contraception. Cochrane Database Syst Rev. 2017;8:CD001324.PubMedGoogle Scholar
  47. 47.
    Roos-Hesselink JW, Cornette J, Sliwa K, Pieper PG, Veldtman GR, Johnson MR. Contraception and cardiovascular disease. Eur Heart J. 2015;36:1728–34. 1734a-1734b CrossRefPubMedGoogle Scholar
  48. 48.
    Tans G, Curvers J, Middeldorp S, Thomassen MC, Meijers JC, Prins MH, et al. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost. 2000;84:15–21.CrossRefPubMedGoogle Scholar
  49. 49.
    Scala C, Leone Roberti Maggiore U, Remorgida V, Venturini PL, Ferrero S. Drug safety evaluation of desogestrel. Expert Opin Drug Saf. 2013;12:433–44.CrossRefPubMedGoogle Scholar
  50. 50.
    Bianca I, Geraci G, Gulizia MM, Egidy Assenza G, Barone C, Campisi M, et al. Consensus document of the Italian Association of Hospital Cardiologists (anmco), Italian Society of Pediatric Cardiology (sicp), and Italian Society of Gynaecologists and Obstetrics (sigo): pregnancy and congenital heart diseases. Eur Heart J Suppl. 2017;19:D256–92.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Wilson W, Taubert KA, Gewitz M, Lockhart PB, Baddour LM, Levison M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association rheumatic fever, endocarditis, and Kawasaki disease committee, council on cardiovascular disease in the young, and the council on clinical cardiology, council on cardiovascular surgery and anesthesia, and the quality of care and outcomes research interdisciplinary working group. Circulation. 2007;116:1736–54.CrossRefPubMedGoogle Scholar
  52. 52.
    Yu AF, Steingart RM, Fuster V. Cardiomyopathy associated with cancer therapy. J Card Fail. 2014;20:841–52.CrossRefPubMedGoogle Scholar
  53. 53.
    Casey PM, Faubion SS, MacLaughlin KL, Long ME, Pruthi S. Caring for the breast cancer survivor's health and well-being. World J Clin Oncol. 2014;5:693–704.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Bordignon S, Aramayo AM, Nunes e Silva D, Grundler C, Nesralla I. Pregnancy after cardiac transplantation. Report of one case and review. Arq Bras Cardiol. 2000;75:515–22.CrossRefPubMedGoogle Scholar
  55. 55.
    McKay DB, Josephson MA, Armenti VT, August P, Coscia LA, Davis CL, et al. Reproduction and transplantation: report on the AST consensus conference on reproductive issues and transplantation. Am J Transplant. 2005;5:1592–9.CrossRefPubMedGoogle Scholar
  56. 56.
    • Cimino FM, Snyder KA. Primary care of the solid organ transplant recipient. Am Fam Physician. 2016;93:203–10. Review of common medical issues affecting patients with solid organ transplant. PubMedGoogle Scholar
  57. 57.
    Costanzo MR, Dipchand A, Starling R, Anderson A, Chan M, Desai S, et al. The international society of heart and lung transplantation guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2010;29:914–56.CrossRefPubMedGoogle Scholar
  58. 58.
    Krajewski CM, Geetha D, Gomez-Lobo V. Contraceptive options for women with a history of solid-organ transplantation. Transplantation. 2013;95:1183–6.CrossRefPubMedGoogle Scholar
  59. 59.
    • Deshpande NA, Coscia LA, Gomez-Lobo V, Moritz MJ, Armenti VT. Pregnancy after solid organ transplantation: a guide for obstetric management. Rev Obstet Gynecol. 2013;6:116–25. Review of management of pregnancy in patients with solid organ transplantation, including discussion of appropriate contraception counseling. PubMedPubMedCentralGoogle Scholar
  60. 60.
    Rafie S, Lai S, Garcia JE, Mody SK. Contraceptive use in female recipients of a solid-organ transplant. Prog Transplant. 2014;24:344–8.CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Morales JM, Andres A, Rengel M, Rodicio JL. Influence of cyclosporin, tacrolimus and rapamycin on renal function and arterial hypertension after renal transplantation. Nephrol Dial Transplant. 2001;16(Suppl 1):121–4.CrossRefPubMedGoogle Scholar
  62. 62.
    Scherrer U, Vissing SF, Morgan BJ, Rollins JA, Tindall RS, Ring S, et al. Cyclosporine-induced sympathetic activation and hypertension after heart transplantation. N Engl J Med. 1990;323:693–9.CrossRefPubMedGoogle Scholar
  63. 63.
    Bennett AL, Ventura HO. Hypertension in patients with cardiac transplantation. Med Clin North Am. 2017;101:53–64.CrossRefPubMedGoogle Scholar
  64. 64.
    Agarwal A, Prasad GV. Post-transplant dyslipidemia: mechanisms, diagnosis and management. World J Transplant. 2016;6:125–34.CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Bloom RD, Crutchlow MF. New-onset diabetes mellitus in the kidney recipient: diagnosis and management strategies. Clin J Am Soc Nephrol. 2008;3 Suppl 2:S38–48.CrossRefPubMedGoogle Scholar
  66. 66.
    Huguelet PS, Sheehan C, Spitzer RF, Scott S. Use of the levonorgestrel 52-mg intrauterine system in adolescent and young adult solid organ transplant recipients: a case series. Contraception. 2017;95:378–81.CrossRefPubMedGoogle Scholar
  67. 67.
    Ramhendar T, Byrne P. Use of the levonorgestrel-releasing intrauterine system in renal transplant recipients: a retrospective case review. Contraception. 2012;86:288–9.CrossRefPubMedGoogle Scholar
  68. 68.
    Kossoy LR, Herbert CM 3rd, Wentz AC. Management of heart transplant recipients: guidelines for the obstetrician-gynecologist. Am J Obstet Gynecol. 1988;159:490–9.CrossRefPubMedGoogle Scholar
  69. 69.
    Zerner J, Doil KL, Drewry J, Leeber DA. Intrauterine contraceptive device failures in renal transplant patients. J Reprod Med. 1981;26:99–102.PubMedGoogle Scholar
  70. 70.
    Yadav BK, Gupta RK, Gyawali P, Shrestha R, Poudel B, Sigdel M, et al. Effects of long-term use of depo-medroxyprogesterone acetate on lipid metabolism in Nepalese women. Korean J Lab Med. 2011;31:95–7.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Cleveland Clinic-Fairview HospitalClevelandUSA

Personalised recommendations